Peripheral Ultrafiltration for Acute Decompensated Heart Failure
Customize your policy alerts
Sign up for Aetna Policy 0741 alerts
Get alerted when Policy 0741 changes without checking for updates manually.
Monitor payer policy activity
This policy governs Aetna's coverage stance for peripheral ultrafiltration as a treatment for hospitalized patients with acute decompensated congestive heart failure (ADHF), including indications considered medically necessary and uses considered experimental/investigational.
No material clinical or coverage changes in this revision.
Coverage Criteria for Peripheral Ultrafiltration
Experimental and investigational uses
Not covered / considered experimental
These uses are considered experimental/investigational per policy
Coverage criteria and evidence synthesis
Coverage considerations based on the evidence summarized in the policy:
Supported by guideline statements and expert reviews
Multiple systematic reviews/meta-analyses report statistically significant greater fluid/weight removal at 48 hours (De Vecchis 2014; Ebrahim 2015)
Heterogeneous trial results; UF may increase risk of worsening renal function in selected trials
Evidence from small nonrandomized studies; effectiveness not established
Aetna considers the following uses experimental and investigational and not covered due to insufficient evidence: intermittent peripheral ultrafiltration (UF) in persons who are not acutely decompensated, scheduled repetitive peripheral UF, peripheral UF for other indications, and peritoneal ultrafiltration as adjunctive therapy in end-stage heart failure. These exclusions apply unless the specific medical necessity criteria for inpatient ADHF with diuretic resistance are met.
Ultrafiltration should not be used as a substitute for appropriately prescribed and administered diuretic therapy or as a quicker mechanical diuresis for inadequately managed diuretics. Instead, UF should be reserved for selected patients with advanced heart failure and true diuretic resistance and not employed in place of optimizing guideline-directed diuretic therapy.
Randomized trial data indicate that UF may be inferior to a stepped pharmacologic strategy in certain populations. In a randomized trial of 188 hospitalized patients with ADHF, worsened renal function, and persistent congestion (Bart et al, 2012), ultrafiltration was inferior to stepped pharmacologic therapy for the primary bivariate endpoint (change in serum creatinine and body weight at 96 hours), driven largely by an increase in creatinine and a higher rate of serious adverse events in the UF arm. Technology assessments have also raised concerns about study limitations and the need for replication of positive findings before routine adoption.
Clinical guideline and evidence syntheses do not support routine use of ultrafiltration for all patients with acute heart failure. The NICE guideline states: “Do not routinely offer ultrafiltration to people with acute heart failure. Consider ultrafiltration for people with confirmed diuretic resistance.” Systematic reviews and meta-analyses report greater short-term fluid and weight removal with isolated UF versus intravenous diuretics at 48 hours, but heterogeneity in trials and safety signals in some randomized studies mean routine UF for unselected ADHF patients is not supported by the evidence.
Coding and Condition Thresholds
| I50.20 - I50.9 | Congestive heart failure |
| I50.84 | End stage heart failure (listed as ICD-10 not covered for indications in the CPB) |
| No codes listed |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Expected
Prior authorization is expected when peripheral ultrafiltration (UF) is billed for acute decompensated heart failure (ADHF) with confirmed diuretic resistance. Providers should obtain prior authorization before performing UF in these situations.
- Prior authorization expected for UF in diuretic-resistant ADHF
NICE Recommendation
Do not routinely offer ultrafiltration for acute heart failure. Consider UF only for people with confirmed diuretic resistance (defined as dose escalation beyond a person's previously recognized dose ceiling or a dose approaching the maximum recommended daily dose without incremental improvement in diuresis).
- NICE: do not routinely offer ultrafiltration; consider only for confirmed diuretic resistance
Documentation to Support Medical Necessity
Document inpatient hospitalization for acutely decompensated congestive heart failure with dyspnea at rest or with minimal activity, and provide objective documentation of diuretic resistance (trial and failure of escalating diuretic therapy as defined above). Include prior diuretic dosing, evidence of dose escalation to near-maximum or beyond previously effective dose without increased diuresis, and clinical indicators supporting need for UF.
- Inpatient hospitalization with dyspnea at rest or minimal activity
- Documentation of diuretic resistance (dose escalation to near-max or beyond prior ceiling without improved diuresis)
- Clinical notes, diuretic dosing history, weight/fluid status, and renal function trends
Requirement to Attempt Diuretics First
Before considering UF, attempt and document appropriate diuretic therapy and demonstrate diuretic resistance. A trial and failure of diuretic therapy is required — UF is reserved for patients with confirmed diuretic resistance.
- Requirement to attempt diuretics first; document dosing and response
- Diuretic resistance definition must be met prior to UF
Evidence and Expert Opinion
Evidence and expert opinion recommend reserving UF for selected patients with advanced heart failure and true diuretic resistance, not for routine use. UF should be part of a comprehensive strategy for control of fluid retention rather than a substitute for inadequately prescribed diuretics.
- Reserve UF for selected advanced HF patients with true diuretic resistance
- UF is not a routine substitute for appropriately managed diuretic therapy
Peritoneal Ultrafiltration Study Outcomes
Studies of peritoneal ultrafiltration (pUF) report outcomes including survival, NYHA class, LVEF, C-reactive protein, body weight, and hospitalization frequency/duration. Although many case series and observational studies report symptomatic and hospitalization benefits, randomized data are limited and peritoneal ultrafiltration is considered experimental as an adjunctive therapy in end-stage heart failure.
- Reported outcomes: survival, NYHA class, LVEF, CRP, body weight, hospitalization frequency/duration
- Evidence limited: many nonrandomized studies; insufficient data to establish effectiveness as adjunctive therapy
Background and Evidence Context
Acute decompensated heart failure (ADHF) refers to an acute worsening of baseline heart-failure symptoms often to severe functional limitation (commonly NYHA Class IV) with evidence of volume overload such as pitting edema, pulmonary rales, elevated filling pressures, and weight gain. The therapeutic goals in ADHF are removal of excess fluid and restoration of diuretic responsiveness. Peripheral ultrafiltration is a device-based convective method for removal of salt and water developed to permit ultrafiltration via peripheral venous access and has been studied as an adjunct when conventional diuretic therapy fails.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.